Abstract:Hypertension is an independent risk factor for stroke. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptor-dependent transcription factors. PPAR agonist fenofibrate has been shown to abrogate increased arterial prepro-endothelin-1 (preproET-1) and superoxide levels in deoxycorticosterone acetate (DOCA)-salt hypertension with unknown mechanism(s). We have reported that ET-1 induces endothelial dysfunction in the carotid arteries via NADPH oxidase-derived superoxide in this low renin hypertension model. Therefore, the present study tested the hypothesis that chronic PPAR activation in vivo reduces blood pressure and endothelial dysfunction via impeding cerebrovascular NADPH oxidase/superoxide and augmenting eNOS cofactor tetrahydrobiopterin (BH4) in DOCA-salt rats. DOCA-salt or sham-operated adult male rats were treated with fenofibrate (150 mg/kg/day) for 4 weeks beginning with DOCA-salt regimen. Oxidative stress markers and endothelial function were determined in the carotid arteries afterwards. Average systolic blood pressure was significantly increased in DOCA-salt rats (1868 vs. 1223 mmHg, DOCA vs. sham), which was blunted by fenofibrate (1868 vs. 1396 mmHg, DOCA vs. DOCA+PPAR, all n=11–16, p<0.01). Concomitantly, treatment with fenofibrate significantly reduced arterial NADPH oxidase activity (44.24.2 vs. 21.61.7 nmol/min/mg tissue DOCA vs. DOCA+PPAR), superoxide level (0.620.04 vs. 0.370.04 nmol/min/mg protein), VCAM-1 expression (0.460.07 vs. 0.280.04, VCAM-1/actin ratio, all n=5–10, p<0.05) and serum lipid peroxidation (TBAR 1.920.08 vs. 5.181.9 mol/L, n=10, p<0.01). Furthermore, treatment with fenofibrate significantly augmented arterial BH4 level (1.230.21 vs. 3.210.88 pmol/mg protein, n=7–8, p<0.05) and endogenous eNOS activity (6.000.40 vs. 12.961.61 nmol/mg protein, DOCA vs. DOCA+PPAR, n=8-9, p<0.05), resulting in improved endothelium-dependent NO-mediated relaxation in response to acetylcholine (39.732.98 vs. 78.313.83%, DOCA vs. DOCA+PPAR, n=9–10, p<0.05). These findings indicate that in vivo PPARá activation prevents progression of hypertension and reduces cerebrovascular endothelial dysfunction via impeding arterial NADPH oxidase-derived superoxide and augmenting eNOS essential cofactor BH4 in low renin mineralocorticoid hypertension. (Supported by American Heart Association grants 0130537Z and 0455594Z (to AFC), China Medical Board (CMB) grant 00730 and the National Natural Sciences Foundation of China grants 39940012 and 30271485 (to JSZ).

Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats.

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Norepinephrine–induced Fibrotic Responses in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Farnesyl Pyrophosphate Synthase Inhibitor, Ibandronate, Improves Endothelial Function in Spontaneously Hypertensive Rats

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Inhibition of Farnesylpyrophosphate Synthase Prevents Angiotensin II-induced Hypertrophic Responses in Rat Neonatal Cardiomyocytes: Involvement of the RhoA/Rho Kinase Pathway

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Fasudil Preserves Lung Endothelial Function and Reduces Pulmonary Vascular Remodeling in a Rat Model of End-Stage Pulmonary Hypertension with Left Heart Disease

Inhibition of Farnesyl Pyrophosphate Synthase Attenuates High Glucose-Induced Vascular Smooth Muscle Cells Proliferation

Folic Acid Delays Development of Atherosclerosis in Low‐density Lipoprotein Receptor‐deficient Mice

Fasudil Prevents Pulmonary Vascular Remodeling in a Rat Model of Pulmonary Hypertension with Left Heart

GW24-e2448 Knockdown of Farnesyl Pyrophosphate Synthase Prevents Cardiac Fibrosis of Spontaneously Hypertensive Ratsin Vivo

Prevention of myocardial fibrosis by using nitrendipine to the spontaneously hypertensive rats

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Angiotensin II-induced Cardiac Fibrosis in Vitro.

In vivo PPAR|[alpha]| activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting tetrahydrobiopterin in mineralocorticoid hypertension

Farrerol Can Attenuate the Aortic Lesion in Spontaneously Hypertensive Rats Via the Upregulation of Enos and Reduction of NAD(P)H Oxidase Activity.